Effect of Sialor in treatment of xerostomia in Sjögren's syndrome.
Sialor, a sialogogue, was studied in a double-blind crossover trial in patients with autoimmune exocrinopathy (Sjögren's syndrome). Sialor appears to frequently alleviate the symptoms of xerostomia and increase salivary flow rate, and it is rarely associated with side effects. Sialor is useful in management of xerostomia in patients with Sjögren's syndrome and may also be of value in the treatment of xerophthalmia.
D000328:Adult; D000368:Aged; D000781:Anethole Trithione / Q000494:pharmacology / Q000627:therapeutic use*; D000840:Anisoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012463:Saliva / Q000502:physiology; D012636:Secretory Rate / Q000187:drug effects; D012859:Sjogren's Syndrome / Q000628:therapy*; D014987:Xerostomia / Q000188:drug therapy*
D000840:Anisoles; D010919:Placebos; D000781:Anethole Trithione